Skip to main content

Table 1 General description of study population

From: Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24 week analysis (RIDAR study)

  N = 161
Age in years, median (IQR) 49 (44–53)
Male sex, n (%) 126 (78.3)
Years since HIV diagnosis, median (IQR) 17 (10–23)
CD4 nadir, median (IQR) 170 (73–290)
History of AIDS, n (%) 47 (29.3)
N° previous ART combinations, median (IQR) 5 (3–7)
Years on ART, median (IQR) 14 (6–18)
Previous ART that included, n (%):  
NRTI 95 (59)
NNRTI 91 (56.5)
PI 128 (79.5)
II 16 (9.9)
ART strategy, n(%):  
Triple therapy 92 (57.1)
Dual therapy 53 (32.9)
Monotherapy 16 (9.9)
Baseline VL (bVL):  
< 50 copies/mL, n (%) 120 (74.5)
50–1000 copies/mL, n (%) 41 (25.5)
Baseline CD4 count, median (IQR) 618 (370–861)
  1. IQR: interquartile range; ART: antiretroviral therapy; NRTI: nucleoside analog reversetranscriptase inhibitors; NNRTI: non-nucleoside analog reverse-transcriptase inhibitors; PI: protease inhibitors; II: integrase inhibitors; VL: viral load